99
Views
6
CrossRef citations to date
0
Altmetric
Review

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

, , &
Pages 605-611 | Published online: 25 Sep 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Haixiao Wen, Chong Lu, Meng Zhang & Xingling Qi. (2023) A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system. Expert Opinion on Drug Safety 22:11, pages 1133-1142.
Read now
Lino Del Pup & Rafael Sánchez-Borrego. (2020) Ospemifene efficacy and safety data in women with vulvovaginal atrophy. Gynecological Endocrinology 36:7, pages 569-577.
Read now
Santiago Palacios & María Jesús Cancelo. (2016) Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. International Journal of Women's Health 8, pages 617-626.
Read now
JoAnn V Pinkerton & Risa Kagan. (2015) Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opinion on Pharmacotherapy 16:17, pages 2703-2714.
Read now

Articles from other publishers (2)

Daniel María Lubián López. (2022) Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World Journal of Clinical Oncology 13:2, pages 71-100.
Crossref
Г. С. Кочарян. (2020) Dyspareunia As a Clinical Problem. Health of Man:3, pages 65-74.
Crossref